Background: The relative potency of prokinetics in patients with gastroparesis has not been systematically studied. This study, therefore, aimed to assess the available data and to compare the effects of different prokinetics on symptoms and gastric emptying rates in patients with gastroparesis. Methods: A systematic search of the literature was performed, covering the period 1980 to March 1998. All identified studies were reviewed and the following data elements assessed: characteristics of study populations; sample sizes; treatment regimes; drug doses; study design; main outcome variables, and the validity of measurements. Results: In 36 studies, 514 patients were treated with prokinetics p.o. Most studies had methodological limitations (i.e. nonvalidated measurement of symptoms or unblinded treatment). The mean improvement in gastric emptying and the reduction in the symptom score was higher in the open trial group than in patients treated double-blind. Overall, erythromycin seems to have had the strongest effect on gastric emptying as compared to domperidone, cisapride or metoclopramide. Concerning gastrointestinal symptoms, the symptom scores appeared to improve more during treatment with erythromycin than with domperidone, metoclopramide or cisapride. Conclusions: Most of the available trials have methodological limitations; this limits the conclusions. However, the data suggest that the motilin-agonist erythromycin is superior with regard to the acceleration of gastric emptying, while both erythromycin and domperidone appear to be the most effective with regard to improvements in the symptom score. Additionally, there is a lack of association between changes in gastric emptying times and improvements in symptoms.

Journal Section:
Original Paper: Motility
Keywords:
Gastroparesis, Prokinetics, Gastric emptying
1.
Horowitz M, Fraser RJL: Gastroparesis: Diagnosis and management. Scand J Gastroenterol 1995;30(suppl 213):7–16.
2.
Drenth JPH, Engels LGJB: Diabetic gastroparesis. Drugs 1992;44:537–553.
[PubMed]
3.
Kendall BJ, McCallum RW: Gastroparesis and the current use of prokinetic drugs. Gastroenterologist 1993;1:107–114.
[PubMed]
4.
Mackie ADR, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR: The effect of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991;5:135–142.
[PubMed]
5.
Mansi C, Savarino V, Vigneri S, Perilli D, Melga P, Sciaba L, DeMartini D, Mela GS: Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am J Gastroenterol 1995;90:1989–1993.
[PubMed]
6.
Nakamura T, Ishii M, Marai Y, Tandoh Y, Terada A, Takebe K: Effect of intravenous administration of EM523L on gastric emptying and plasma glucose levels after a meal in patients with diabetic gastroparesis: A pilot study. Clin Ther 1994;16:989–999.
[PubMed]
7.
Rosa E’Silva L, Troncon LEA, Oliveira RB, Iazigi N, Foss M: Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995;9:179–183.
[PubMed]
8.
Cooper T, Cutts T, Abell TL, West L, Cardoso S: Long-term cisapride therapy improves quality of life measures in patients with symptoms of gastroparesis. Gastroenterology 1991;100:A432.
9.
Champion MC, Gulenchyn K, Braaten J, Irvine P, O’Leary T, Edwards A, Gay J: Cisapride (Prepulsid) is effective in the management of diabetic gastroparesis. J Gastroenterol Hepatol 1989;4(suppl 3):25.
10.
McCallum RW, Plankey MW, Fisher KL: Chronic oral cisapride therapy increases solid meal gastric emptying and improves symptoms in patients with gastric stasis. Gastroenterology 1987;92:A1337.
11.
Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJC: Effect of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987;93:311–315.
[PubMed]
12.
Horowitz M, Maddox A, Harding PE, Maddern GJ, Chatterton BE, Wishart J, Shearman DJ: Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987;92:1899–1907.
[PubMed]
13.
Havelund T, Øster-Joergensen E, Eshoej O, Larson MM, Lauritsen K: Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus. Acta Med Scand 1987;222:339–343.
[PubMed]
14.
Corinaldesi R, Raiti C, Stanghellini V, Monetti N, Rea E, Salgemini R, Paparo GF, Barbara L: Comparative effect of oral cisapride and metoclopramide on gastric emptying of solids and symptoms in patients with functional dyspepsia and gastroparesis. Curr Ther Res 1987;42:428–435.
15.
Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR: Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989;96:704–712.
[PubMed]
16.
De Caestecker JS, Ewing DJ, Tothill P, Clarke BF, Heading RC: Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: An eight week double-blind crossover study. Aliment Pharmacol Ther 1989;3:69–81.
[PubMed]
17.
Valenzuela G, Fisher K, Davenport K, Plankey M, McCallum RW: Long-term subjective and objective effects of cisapride in the treatment of gastroparesis. Gastroenterology 1990;98:A399.
18.
Boivin M, Diamant N: Cisapride in the treatment of gastroparesis. Clin Invest Med 1991;11:41.
19.
Abell TL, Camilleri M, DiMagnao EP, Hench VS, Zinsmeister AR, Malagelada JR: Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991;36:616–620.
[PubMed]
20.
Champion MC, Braaten J, Gulenchyn K: Domperidone (motilium) compared to cisapride (prepulsid) in the management of gastroparesis. Am J Gastroenterol 1991;86:1309.
21.
Richards RD, Valenzuela GA, Davenport KG, Fisher KLK, McCallum RW: Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993;38:811–816.
[PubMed]
22.
Corinaldesi R, Stanghellini V, Tosetti C, Rea E, Corbelli C, Marengo M, Barabara L: The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993;44:429–432.
[PubMed]
23.
Rothstein RD, Alavi A, Reynolds JC: Electrogastrography in patients with gastroparesis and effect of long-term cisapride. Dig Dis Sci 1993;38:1518–1524.
[PubMed]
24.
Patterson DJ, Eisenberg B, Skinner SF: Cisapride is effective long-term therapy for diabetic gastroparesis. Gastroenterology 1993;104:A564.
25.
Dworkin BM, Rosenthal WS, Casellas AR, Girolomo R, Lebovics E, Freeman S, Bennet-Clark S: Open label study of long-term effectiveness of cisapride in patients with idiopathic gastroparesis. Dig Dis Sci 1994;39:1395–1398.
[PubMed]
26.
Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A: Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med 1982;96:444–446.
[PubMed]
27.
McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, Deren J, Ippoliti A, Olsen HW, Falchuk K, Hersh T: A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6:463–467.
[PubMed]
28.
Loo FD, Palmer DW, Soergel KH, Kalbfleisch JH, Wood CM: Gastric emptying in patients with diabetic mellitus. Gastroenterology 1984;86:485–494.
[PubMed]
29.
Ricci DA, Saltzmann MB, Meyer MDC, Callachan C, McCallum RW: Effect of Metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 1985;7:25–32.
[PubMed]
30.
Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, van Thiel DH: Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci 1985;30:10–15.
[PubMed]
31.
Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S: Comparisation of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Care 1993;16:1511–1514.
32.
Urbain JLC, Vantrappen G, Janssens J, Van Cutsem E, Peeters T, De Roo M: Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids. J Nucl Med 1990;31:1490–1493.
[PubMed]
33.
Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, DeRoo M, Muls E, Bouillon R: Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990;322:1028–1031.
[PubMed]
34.
Richards RD, Davenport K, McCallum RM: The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203–207.
[PubMed]
35.
Pan DY, Chen GH, Chang CS, Ho KS, Poon SK, Huang CK, Kao CH, Wang SJ: Effect of oral erythromycin on patients with diabetic gastroparesis. Chung Hua I Hsueh Tsa Chih Taipei 1995;55:447–451.
36.
Kao CH, Wang SJ, Pang DY: Effects of oral erythromycin on upper gastrointestinal motility in patients with non-insulin-dependent diabetes mellitus. Nucl Med Commun 1995;16:790–793.
[PubMed]
37.
Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJC: Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30:1–9.
[PubMed]
38.
Champion MC, Gulenchyn K, O’Leary T, Irvine P, Edwards A, Braaten J, Gay J: Domperidone (motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Am J Gastroenterol 1987;82:975.
39.
Koch KL, Stern RM, Stewart WR, Vasey MW: Gastric emptying and myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term domperidone treatment. Am J Gastroenterol 1989;84:1069–1075.
[PubMed]
40.
Bailar JC: The promise and problems of meta-analysis. N Engl J Med 1997;337:559–561.
[PubMed]
https://doi.org/10.1056/NEJM199708213370810
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1999
You do not currently have access to this content.